Antidepressant-like effect of novel 5-HT3 receptor antagonist N-n-butyl-3-ethoxyquinoxalin-2-carboxamide (6p): An approach using rodent behavioral antidepressant tests

Indian Journal of Pharmacology

Volumn 45, Issue 4, 2013, Pages 348-353

  Bhatt, Shvetank ^a   Mahesh, Radhakrishnan ^a   Devadoss, Thangaraj ^a   Jindal, Ankur ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

5 HT 3 receptor antagonists; antidepressant; forced swim test; quinoxaline; serotonin

Indexed keywords

5 HYDROXYTRYPTOPHAN; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; N N BUTYL 3ETHOXYQUINOXALIN 2 CARBOXAMIDE; PAROXETINE; RESERPINE; SEROTONIN 3 ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DEPRESSION; FORCED SWIMMING TEST; HEAD TWITCH; HYPOTHERMIA; INDUCED HYPOTHERMIA; NONHUMAN; OLFACTORY BULBECTOMY; RAT;

5-HT3 RECEPTOR ANTAGONISTS; ANTIDEPRESSANT; FORCED SWIM TEST; QUINOXALINE; SEROTONIN;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BODY TEMPERATURE; EXPLORATORY BEHAVIOR; GUINEA PIGS; HINDLIMB SUSPENSION; ILEUM; MICE; MOTOR ACTIVITY; OLFACTORY BULB; QUINOXALINES; RATS; RATS, WISTAR; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; SWIMMING;

EID: 84881411824     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.115014     Document Type: Article

References (26)

1. Peters JA, Lambert JJ. Electrophysiology of 5-HT3 receptors in neuronal cell lines. Trends Pharmacol Sci 1989;10: 172-5.
2. Davies PA, Wang W, Hales TG, Kirkness EF. A novel class of ligandgated ion channel is activated by Zn2+. J Biol Chem 2003;278:712-7.
3. Connolly CN, Wafford KA. The Cys-loop superfamily of ligand-gated ion channels, the impact of receptor structure on function. Biochem Soc Trans 2004;32:529-34.
4. Richardson BP, Engel G, Donatsch P, Stadler PA. Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs. Nature 1985; 316:126-31.
5. Girish MB, Bhuvana K, Nageshraju G, Sarala N. A novel atypical antidepressant drug. Agomaeltine-A review. Int J Pharm Biomed Res 2010;1:113-6.
6. Shelton RC. Classification of Antidepressants and Their Clinical Implications. Primary Care Companion. J Clin Psychol 2003;5:27-32.
7. Ayuso-Gutierrez JL. Old and New Antidepressants. Where are we? World J Biol Psychol 2002;3:112-4.
8. Rajkumar R, Mahesh R, Minasri B. Antidepressant-like effects of serotonin type-3 antagonist, ondansetron. an investigation in behavior-based rodent models. Behav Pharmacol 2008;19:29-40.
9. Devadoss T, Pandey DK, Mahesh R, Yadav SK. Effect of acute and chronic treatment with QCF-3 (4-benzylpiperazin-1-yl)(quinoxalin-2-yl)methanone, a novel 5-HT 3 receptor antagonist, in animal models of depression. Pharmacol Rep 2010;62:245-57.
10. Kelley SP, Bratt AM, Hodge CW. Targeted gene deletion of the 5-HT 3A receptor subunit produces an anxiolytic phenotype in mice. Eur J Pharmacol 2003;461:19-25.
11. Haus U, Varga B, Stratz T, Spath M, Muller W. Oral treatment of fibromyalgia with tropisetron given over 28 days. influence on functional and vegetative symptoms, psychometric parameters and pain. Scand J Rheumatol Suppl 2000;113:55-8.
12. Faris PL, Eckert ED, Kim SW. Evidence for a vagal pathophysiology for bulimia nervosa and the accompanying depressive symptoms. J Affect Disord 2006;92:79-90.
13. Hibert MF, Hoffmann R, Miller RC, Carr AA. Conformation-activity relationship study of 5-HT3 receptor antagonists and a definition of a model for this receptor site. J Med Chem 1990;33:1594-600.
14. Bourin M. Is it possible to predict the activity of a new antidepressant in animals with simple psychopharmacological tests? Fund Clin Pharmacol 1990;4:49-64.
15. Lucki I. The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav Pharmacol 1997;8:523-32.
16. Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: A primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977;229:327-36.
17. Steru L, Chermat R, Thierry B, Simon P. The tail suspension test. a new method for screening antidepressant drugs. Psychopharmacology 1985;85:367-70.
18. Kelly JP, Wyrnn AS, Leonard BE. The olfactory bulbectomized rat as a model of depression. an update. Pharmacol Ther 1997;74:299-316.
19. Paton WD, Zar AM. The origin of acetylcholine released from guinea-pig intestine and longitudinal muscle strips. J Physiol 1968;194:13-33.
20. MacKay D. How should values of pA2 and affinity constants for pharmacological competitive antagonists be estimated? J Pharm Pharmacol 1978:30:312-3.
21. Bourin M, Chenu F, Ripoll N, David DJ. A proposal of decision tree to screen putative antidepressants using forced swim and tail suspension tests. Behav Brain Res 2005;164:266-9.
22. Martin P, Massol J, Soubrie P, Puech AJ. Effects of triiodothyronine (T 3) on the potentiation by antidepressants of L-5-hydroxytryptophan-induced head-twitches in mice. Prog Neuropsychopharmacol Biol Psychiatry 1989;13:735-48.
23. Englert LF, Ho BT, Taylor D. The effects of (-)-delta9- tetrahydrocannabinol on reserpine- induced hypothermia in rats. Br J Pharmacol 1973;49:243-52.
24. Hoomissen JV, Kunrath J, Dentlinger R, Lafrenz A, Krause M, Azar A. Cognitive and locomotor/exploratory behavior after chronic exercise in the olfactory bulbectomy animal model of depression. Behav Brain Res 2011;222:106-16.
25. Rajkumar R, Mahesh R. The auspicious role of the 5-HT3 receptor in depression. A probable neuronal target? J Psychopharmacol 2010;24:455-69.
26. Kelley SP, Bratt AM, Hodge CW. Targeted gene deletion of the 5-HT3A receptor subunit produces an anxiolytic phenotype in mice. Eur J Pharmacol 2003;461:19-25.